Clinical UpdatesDrug News

An anesthetic used in lethal injections will no longer be made by its only U.S. manufacturer because the company does… »   

Johnson & Johnson, already under fire for a string of product recalls, has another public relations issue on its hands… »   

Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don’t… »   

GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its… »   

Britain’s health costs agency has confirmed a plan to end restrictions on the use by the National Health Service (NHS)… »   

Johnson & Johnson faulted lax cleaning procedures and other problems at a manufacturing plant behind massive recalls of medicines like… »   

Novartis advanced its bid to copy Roche’s multi-billion dollar antibody drug rituximab on Monday, starting phase II trials for its… »   

French drugmaker Sanofi Aventis SA said on Sunday it was in discussions with U.S. bid target Genzyme Corp over ways… »   

The incoming chairman of the U.S. congressional committee that has been investigating Johnson & Johnson’s series of recalls of consumer… »   

Amgen Inc’s chief executive met with the top executive of Swiss biotech firm Actelion Ltd to discuss his interest in… »   

Hundreds of Kenyans living with HIV protested outside EU offices in Nairobi on Thursday against a deal they say may… »   

Dugmaker Cephalon Inc plans to acquire a stake in Australian biotechnology company Mesoblast Ltd as well as rights to develop… »   

Investors welcomed the sudden departure of Pfizer Inc CEO Jeffrey Kindler by pushing up the stock in the hopes that… »   

Companies and consumers both feel the U.S. Food and Drug Administration does a good job, but high-profile drug recalls have… »   

European regulators on Friday set out broad guidelines for the approval of biosimilar antibody drugs, including lower hurdles than for… »